Cross-Sector entity

MiMedx

Company MDXG
7

Of the tracked stories, 2 of 3 also mention Alkermes, the most common co-covered peer. legal-tech accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. MiMedx appears in 3 tracked Cross-Sector stories from February 26, 2026.

3 verified stories tracked

Last mentioned: Feb 26, 2026

Entity pulse

Recent coverage · MiMedx

3 stories
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about MiMedx

Of the tracked stories, 2 of 3 also mention Alkermes, the most common co-covered peer. legal-tech accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. MiMedx appears in 3 tracked Cross-Sector stories from February 26, 2026. The tracked stories average 20 original sources each.

Stories tracked
3
Sources per story
20

Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering MiMedx. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning MiMedx 3

Biotech pharma Positive 7

Rare Disease Commercialization and M&A Drive Mid-Cap Biotech Growth

Mid-cap biotech and specialty pharma companies are demonstrating strong commercial maturation, led by record-breaking rare disease revenues and strategic consolidation. Key players like Mirum and Acadia are scaling rapidly, while Alkermes’ acquisition of Avadel signals a shift toward aggressive portfolio expansion in the neuroscience space.

20 sources
Healthcare market trends Positive 7

Health Tech Earnings: AI Integration and Orphan Drugs Drive Q4 Sector Growth

The Q4 2025 earnings cycle for healthcare and health IT firms reveals a sector-wide shift toward AI-driven diagnostics and high-margin orphan drug commercialization. While medical device firms face cyclical equipment sales challenges, specialized biotech and diagnostic players like Veracyte and Soleno are reporting record profitability and rapid market penetration.

20 sources
Legal legal tech Positive 7

AI Governance and Regulatory Shifts Dominate Q4 2025 Legal & RegTech Earnings

The Q4 2025 earnings cycle reveals a significant acceleration in AI-driven legal automation and the maturation of regulated digital asset frameworks. Companies like CS Disco and Circle are setting new benchmarks for AI adoption and compliant transaction volumes, while healthcare and insurance sectors navigate tightening regulatory oversight.

20 sources

Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)